Clinical trial NCT04569760: Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
Official title: Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Generalized Anxiety Disorder
Social Anxiety Disorder
Panic Disorder
Agoraphobia
Keywords: Anxiety Disorders
Cannabinoids
Cannabis
Cannabidiol
Lead sponsor: McMaster University
Sponsor class: OTHER
Collaborators: name: MediPharm Labs Corp
First posted: 2020-09-30
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This proposed study aims to evaluate the efficacy of a daily oral cannabinoid oil preparation in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years. The study will also evaluate the relationship between inflammation, anxiety and cannabinoids using biological markers as well as examine the neuro-cognitive effects of cannabinoid treatment.

Detailed description: The study will be a randomized, double-blind, placebo-controlled parallel design comparing the efficacy and safety of a flexibly dosed cannabinoid oil preparation versus matching placebo for the treatment of adults, aged 21 to 65 years with a primary Diagnostic and Statistical Manual 5 (DSM-5) anxiety disorder: Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD), or agoraphobia. A total 50 participants (n=25/cell) who meet the inclusion criteria will be randomized to receive 1 of 2 treatments in a 1:1 ratio: cannabinoid oil preparation or matching placebo, with the possibility of dose titration during this 8-week period. The outcomes of this research will make a significant contribution to enhance our current understanding of the effects of cannabis in anxiety disorders.

To be involved in this study, the study doctor will first check that the participant is qualified. This is called screening, and will involve a clinical assessment, physical exam and urine tests. This visit may take up to 3 hours to complete.

If the participant successfully completes screening the participant will start treatment in one of the two assigned treatment groups. Treatment is 8 weeks. Participants will come to the study clinic 6 times during the treatment phase of the study. Each visit will last 1 to 2 hours. Each visit will involve reporting any side effects that the participant may have experienced, completing questionnaires about mood and anxiety symptoms, sleep, overall functioning and alcohol and drug use. Participants will also be assessed by the study doctor. The first and last visits will also involve blood work and completing a number of tasks on the computer, which measure focus, attention and memory.

Each participant will be involved in the study for a maximum of 10 weeks. This includes the screening visit and follow-up visit.

Eligibility criteria: Inclusion Criteria:

1. Male or female outpatients 21-65 years of age with a primary psychiatric diagnosis of either GAD, SAD, PD or agoraphobia as defined by DSM-5 criteria and a HAM-A score greater than or equal to 22.
2. Physical exam and laboratory findings without clinically significant abnormalities. Screening bloodwork values for hematology and chemistry are to be Within Normal Limits.
3. Participants must agree to abstain from recreational cannabis use for the duration of the study.
4. Concomitant psychotropic medication use will be allowed provided that the dose has been stable for 8 weeks prior to randomization. (including antidepressants, anti-psychotics, benzodiazepines, and stimulants)

Exclusion Criteria:

1. Current recreational or medicinal use of cannabis within 4 weeks of study initiation.
2. Participants with a lifetime history of cannabis use disorder or other substance use disorders (except tobacco use disorder) will be excluded.
3. Participants with a lifetime history of daily cannabis use will be excluded.
4. Dose changes of concomitant medication will not be permitted during the study period.
5. Participants currently using medications that are CYP3A4, CYP2C19 or CYP2D6 inhibitors or inducers which includes but is not limited to: tricyclic antidepressants, topiramate, clobazam, amitriptyline, fentanyl, the related opioids sufentanil and alfentanil, codeine, oxycodone, macrolides, calcium channel blockers, cyclosporine, sildenafil, tadalafil, antihistamines, antiretrovirals, atorvastatin and simvastatin, warfarin and valproate or other anti-epileptics.
6. Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months), or women who are planning on becoming pregnant.
7. Diagnosis of any of the following mental disorders as defined by the DSM-5: a lifetime history of schizophrenia or any other psychosis, mental retardation, organic medical disorders, bipolar disorder. Entry of patients with obsessive compulsive disorder or posttraumatic stress disorder will be permitted if the anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample.
8. Major depression will be allowed if not severe (Montgomery Asberg Depression Rating Scale-MADRS28≥ 25). Patients with significant suicidal ideation (MADRS item 10 score \> 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
9. Participants with a family history of psychosis will be excluded.
10. Participants who have a history of adverse reactions to cannabis will be excluded.
11. Participants who have severe cardiovascular, immunological, liver, or kidney disease, arrhythmia or a history of arrhythmias will be excluded.

    -

Primary outcomes:
measure: Hamilton Anxiety Rating Scale (HAM-A)
timeFrame: Change from baseline to week 8
Secondary outcomes:
measure: Clinical Global Impression - Severity (CGI-S)
timeFrame: Change from baseline to week 8
measure: Clinical Global Impression - Improvement (CGI-I)
timeFrame: Change from baseline to week 8
measure: Generalized Anxiety Disorder-7 (GAD-7)
timeFrame: Change from baseline to week 8
measure: Liebowitz Social Anxiety Scale- Self Report (LSAS-SR)
timeFrame: Change from baseline to week 8
measure: Panic and Agoraphobia Scale (PAS)
timeFrame: Change from baseline to week 8
measure: Quick Inventory of Depressive Symptomology (QIDS)
timeFrame: Change from baseline to week 8
measure: Sheehan Disability Scale (SDS)
timeFrame: Change from baseline to week 8
measure: World Health Organization Disability Assessment Scale (WHODAS 2.0)
timeFrame: Change from baseline to week 8
measure: Insomnia Severity Index (ISI)
timeFrame: Change from baseline to week 8
measure: Marijuana Craving Questionnaire
timeFrame: Change from baseline to week 8
measure: Obsessive Compulsive Inventory-Revised (OCI-R)
timeFrame: Change from baseline to week 8
measure: PTSD Checklist (PCL-5)
timeFrame: Change from baseline to week 8
measure: MINI-Plus: Mini International Neuropsychiatric Interview (MINI)
timeFrame: Change from baseline to week 8
measure: MADRS - Montgomery Asberg Depression Rating Scale
timeFrame: Change from baseline to week 8
measure: The Columbia Suicide Severity Rating Scale,
timeFrame: Change from baseline to week 8
measure: DEQ - Drug Effects Questionnaire
timeFrame: Change from baseline to week 8
measure: CCCAB - Cannabinoid-induced Cognitive Consequences Assessment Battery
timeFrame: Change from baseline to week 8
measure: Neurocognitive tests
timeFrame: Change from baseline to week 8
measure: Inflammatory markers
timeFrame: Change from baseline to week 8
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: MacAnxiety Research Centre
state: Ontario
Study officials:
affiliation: Hamilton Health Sciences Corporation
name: Michael Van Ameringen, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: